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carried out independently by 2 researchers. We used tools of Scottish Intercollegiate 
Guidelines Networks (SIGN) for assessment of the quality of studies. Results: The 
effectiveness of the ST2 was assessed by means of association with prognosis(risk 
ratio (RR) or odds ratio (OR), accuracy of forecasting of the prognosis, stratification of 
risk), correlation with the comparative test and relevance with clinical symptoms. 
The RR or OR of the death arising from ST2 was 1.01~4.56, the RR of hospitalization 
was 1.054~2.4. On the other hand, RR of hospitalization of BNP was 1.15~2.0, the RR 
or OR of death arising from NT pro-BNP was 0.19~1.241. The sensitivity/specificity 
of the test was 64~87%/51~82% and AUC values were 0.689~0.84. The stratification 
of risk (Net Reclassification Improvement, NRI) on the death rate were reported to 
be significant at 9.4 and 9.9 in the 2 studies, but 1 study reported that stratification 
of risk of the death rate was 0.049 and stratification of risk of hospitalization rate 
was 0.0638. The correlation coefficients with BNP was 0.16~0.409 and with NT pro-
BNP was 0.28~0.523. The correlation coefficient with the peak VO2was 0.30 and with 
6-minute walk distance was 0.22. ConClusions: The ST2 is effective in determining 
the prognosis of patients with heart failure.
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objeCtives: Pharmacists, working as part of the multidisciplinary team, have a 
relevant role in improving clinical outcomes through providing educational inter-
vention, medicine management intervention, or a combination of both. The purpose 
of this study was to determinate the impact of a telephone counseling intervention 
administered bi-monthly by pharmacist on patients’ beliefs about antihyperten-
sive medicines and blood pressure control. Methods: Subjects were selected on 
a time frame of two months according to their attendance to the Centre for the 
Diagnosis and Therapy of Arterial Hypertension of Cardarelli Hospital of Naples, 
located in the South of Italy. Participants were randomly assigned to either control 
group (usual care) or intervention group (educational intervention). The study was 
developed in the framework of the Multidisciplinary Health Care Team (GOIP) for 
Diagnosis and Therapy of Arterial Hypertension activities. The intervention con-
sisted of an educational/counseling session based on patients’ needs assessment 
and provided by a pharmacist bi-monthly for one year via telephone. Results: 
A total of 164 patients (80 in the control group, CG, and 84 in the intervention 
group, IG) were recruited. At the end of follow-up, the reduction in SBP and DPB 
was significant in IG (p< 0.001) and there were also significant differences between 
IG and CG for both Necessity and Concern score (t= 5.74, p< 0.001; t= -7.86, p< 0.001 
respectively). Patients were divided into four attitudinal groups based on their BMQ 
results and data showed that at t= 12 83,3% of IG patients was “Accepting” and 15.5% 
was “Ambivalent”. None “Skeptical” patients were found in the IG and only 1,2% was 
“Indifferent”. ConClusions: Telephone-administered pharmacist intervention can 
improve BP control modifying patients beliefs and concerns about treatments, as 
well as involving patients as participants in the management of their health.
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bACkgRound: Current guidelines recommend a minimum of 3 months’ antico-
agulation (AC) following venous thromboembolism (VTE). The decision to prolong 
treatment depends on clinicians’ perception of benefit-risk, patient characteris-
tics, and preferences. As evidence is limited for the optimal duration of therapy, 
considerable variability exists in routine care. objeCtives: To describe the duration 
of AC following VTE in clinical practice in England and identify factors associated 
with longer duration. Methods: Retrospective study of all VTE events between 1 
April 2008 and 31 March 2012 in linked Clinical Practice Research Datalink/Hospital 
Episode Statistics databases. We defined VTEs by Read or ICD-10 codes with antico-
agulant prescription within 45 days after VTE or hospital discharge. We used multi-
variate Cox regression to identify factors associated with AC duration (event= end of 
AC). Results: Of 11,353 VTEs, 45.0% were PEs and 48.5% were in men. Mean patient 
age was 63.9 years. Median AC duration was 219 days. In the Cox model, previous VTE 
was strongly associated with increased AC duration (HR: 0.46 [95%CI 0.42-0.50]). Other 
factors associated with longer AC duration were age > 40 (vs ≤ 40, 41-64: 0.82 [0.76-0.89]; 
65-79: 0.74 [0.68-0.80]; ≥ 80: 0.82 [0.75-0.90]), PE (vs DVT, 0.71 [0.68-0.75]), active cancer 
(vs unprovoked VTE, 0.86 [0.80-0.92]), hospitalisation (vs no hospitalisation, leading 
to hospitalisation: 0.81 [0.77-0.85], during hospitalisation: 0.72 [0.66-0.79]), and history 
of systemic arterial thromboembolism (0.72 [0.56-0.91]). Other factors retained by the 
Cox model were gender, body mass index, geographic region, and previous major 
bleeding. ConClusions: In routine practice in England, most patients received more 
than 6 months of AC therapy after VTE. Factors associated with prolonged AC cor-
responded to risk factors commonly thought to increase VTE recurrence. Consensus 
concerning the optimal length of AC treatment following acute VTE (beyond 3 months) 
may help to minimize variability in patient care in the future.
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objeCtives: It is well-known that stroke is one of the primary causes of death 
with low survival rates in Turkey. This study investigates how many months 
aggressive payer policies encouraging VKA prescribing are expected across the EU5, 
together with extended pricing and reimbursement negotiations following each 
NOAC label expansion, in order to manage healthcare budgets.
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objeCtives: To establish whether identification of patients with statin-associated 
symptoms (SAS), particularly muscle-related symptoms (MRS) in real-world prac-
tice is aligned with the latest clinical consensus. Methods: A web-based survey 
was conducted in France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, 
and the UK in February–March 2014. Sixty clinicians per country answered ques-
tions about clinical criteria used to identify patients with SAS. These criteria from 
real-world practice were compared with those recommended in the 2015 European 
Atherosclerosis Society Consensus Panel Statement (EASCPS) to explore their align-
ment. Results: Overall, 319 clinicians (76% cardiologists) completed the survey. 
Almost all clinicians (average 98%; range across countries [RAC] 97–100%) saw and 
considered MRS in patients receiving statins to indicate SAS. Across countries, an 
average of 69% of clinicians reported testing for elevated creatine kinase (CK) lev-
els in all patients newly prescribed statins; an average of 52% reported testing in 
patients who displayed MRS. On average, 77% of clinicians (RAC 68–85%) reported 
trying ≥ 2 statins before considering MRS to be SAS; 65% (RAC 57–73%) tried ≥ 3 
statins. Most clinicians (average 74%; RAC 63–85%) reported rechallenging patients 
with the same statin to confirm whether MRS were SAS. Of those who did not 
rechallenge, 61% (RAC 50–67%) reported discontinuing the statin to test whether 
MRS resolved, and an average of 38% (RAC 32–45%) reported using a combination 
of rechallenging, discontinuing, and lowering the dose of statin to confirm SAS. Of 
the reported criteria used for determining SAS, CK testing upon MRS and trial of ≤ 3 
statins are consistent with the latest EASCPS, although routine CK testing and statin 
rechallenge are not fully consistent. ConClusions: This survey suggests that the 
clinical criteria used to identify patients with SAS across eight European countries 
are broadly consistent with the current clinical consensus in Europe.
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objeCtives: To compare the management of statin-treated patients with hyper-
cholesterolemia and statin-associated symptoms (SAS) in real-world practice 
across eight European countries with the latest European Atherosclerosis Society 
Consensus Panel Statement (EASCPS) and decisions of national health technol-
ogy assessment (HTA) agencies. Methods: A web-based survey was conducted 
in France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, and the UK in 
February–March 2014. Sixty clinicians (specialists and general/family physicians, 2:1 
ratio) per country answered questions about the management of patients with SAS. 
Targeted literature searches were performed (June 2015) to identify HTA decisions 
before and after the survey for comparison with survey outcomes. Results: 
Overall, 319 clinicians (76% cardiologists) completed the survey. An average of 58% 
of clinicians (range across countries 40–65%) reported using a lower dose of statin 
in patients who were unable to tolerate statins at the label-recommended dose, a 
practice which is recommended by the EASCPS. On average, 52% of patients known 
to have SAS continued to receive a low-dose statin, usually with other lipid-lowering 
therapies (LLTs). Of the remaining 48%, 37% received alternative LLT only and an 
average of 11% of patients with SAS received no statin or alternative LLT. Ezetimibe 
was the most common first choice of non-statin LLT for patients with SAS, either 
without concomitant statins (average across countries 74% clinicians) or in com-
bination with a low-dose statin as recommended by the EASCPS (average across 
countries 79% clinicians). Ezetimibe is recommended by most national and regional 
HTA agencies in the surveyed countries despite some agencies’ concerns about 
the limitations of the supporting evidence. ConClusions: This survey identified 
potential treatment gaps in the management of patients with SAS: in some cases 
patients receive no LLT, leaving them without treatment for hypercholesterolemia.
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objeCtives: ST2 reflects activity of the cardioprotective signal and it is a prognostic 
marker in heart failure. The aim is to assess the effectiveness of the ST2 for determi-
nation of the prognosis of patient with heart failure. Methods: We searched the 8 
Korean databases and overseas databases including Ovid-MEDLINE, Ovid-EMBASE and 
Cochrane Library. Total 365 studies were searched and 19 studies were included in the 
final assessment. Each of the stages from literature search and extraction of data were 
